Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH, Genentech, Inc., Merck KGaA, Pfizer, and AstraZeneca; collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-419-1400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.11 million
Profitability
Miscellaneous
Employees44
OptionableOptionable
Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions
What is Syndax Pharmaceuticals' stock symbol?
Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."
How were Syndax Pharmaceuticals' earnings last quarter?
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) announced its quarterly earnings results on Monday, November, 5th. The company reported ($0.68) EPS for the quarter, topping the Zacks' consensus estimate of ($0.76) by $0.08. The business had revenue of $0.38 million for the quarter, compared to analysts' expectations of $0.38 million. Syndax Pharmaceuticals had a negative return on equity of 91.11% and a negative net margin of 3,185.75%. View Syndax Pharmaceuticals' Earnings History.
When is Syndax Pharmaceuticals' next earnings date?
What price target have analysts set for SNDX?
6 brokerages have issued twelve-month price objectives for Syndax Pharmaceuticals' shares. Their forecasts range from $6.00 to $40.00. On average, they expect Syndax Pharmaceuticals' stock price to reach $18.60 in the next twelve months. This suggests a possible upside of 230.5% from the stock's current price. View Analyst Price Targets for Syndax Pharmaceuticals.
What is the consensus analysts' recommendation for Syndax Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syndax Pharmaceuticals.
Has Syndax Pharmaceuticals been receiving favorable news coverage?
News articles about SNDX stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Syndax Pharmaceuticals earned a news sentiment score of 1.4 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the near future.
Who are some of Syndax Pharmaceuticals' key competitors?
Some companies that are related to Syndax Pharmaceuticals include Crinetics Pharmaceuticals (CRNX), Flexion Therapeutics (FLXN), Arvinas (ARVN), Assembly Biosciences (ASMB), CymaBay Therapeutics (CBAY), Collegium Pharmaceutical (COLL), MacroGenics (MGNX), NuCana (NCNA), Zymeworks (ZYME), Obseva (OBSV), BioSpecifics Technologies (BSTC), Theratechnologies (THERF), Prothena (PRTA), Innate Pharma (IPHYF) and GlycoMimetics (GLYC).
Who are Syndax Pharmaceuticals' key executives?
Syndax Pharmaceuticals' management team includes the folowing people:
- Dr. Briggs W. Morrison, CEO & Director (Age 58)
- Mr. Michael A. Metzger, Pres & COO (Age 47)
- Mr. Richard P. Shea, CFO & Treasurer (Age 66)
- Dr. Michael L. Meyers, Chief Medical Officer & Sr. VP (Age 67)
- Dr. Peter Ordentlich, Co-Founder & Chief Scientific Officer (Age 49)
When did Syndax Pharmaceuticals IPO?
(SNDX) raised $66 million in an IPO on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.
How do I buy shares of Syndax Pharmaceuticals?
Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syndax Pharmaceuticals' stock price today?
One share of SNDX stock can currently be purchased for approximately $5.6271.
How big of a company is Syndax Pharmaceuticals?
Syndax Pharmaceuticals has a market capitalization of $139.78 million and generates $2.11 million in revenue each year. The company earns $-60,800,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Syndax Pharmaceuticals employs 44 workers across the globe.
What is Syndax Pharmaceuticals' official website?
How can I contact Syndax Pharmaceuticals?
Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]
MarketBeat Community Rating for Syndax Pharmaceuticals (NASDAQ SNDX)
MarketBeat's community ratings are surveys of what our community members think about Syndax Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
